|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We, therefore, performed a case-control study to investigate the association of seven selected single nucleotide polymorphisms (SNPs), in genes coding for excision repair cross-complimentary group 1 (ERCC1: rs11615, rs3212986, rs2298881), nuclear factor ĸB (NFKB2: rs7897947, rs12769316), bone morphogenetic protein 4 (BMP4: rs1957860), complement receptor 1 (CR1: rs7525160) and del/ins polymorphism in the family hypoxia inducible factor 2 gene (EGLN2: rs10680577), with non-small cell lung cancer (NSCLC) risk.
|
31177178 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In addition, the association was more pronounced in the group of >60 years of age. rs10680577 polymorphism is associated with the risk of non-small cell lung cancer in a Chinese population.
|
24894671 |
2014 |
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Ins/Del polymorphism (rs10680577) in RERT-lncRNA was correlated with the risk, major clinicopathological features, and prognosis of lung cancer patients, and the patients with Ins/Del + Del/Del genotype carriers had higher expressions of RERT-lncRNA and EGLN2 than those with Ins/Ins carriers.
|
30073577 |
2019 |
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Ins/Del polymorphism (rs10680577) in RERT-lncRNA was correlated with the risk, major clinicopathological features, and prognosis of lung cancer patients, and the patients with Ins/Del + Del/Del genotype carriers had higher expressions of RERT-lncRNA and EGLN2 than those with Ins/Ins carriers.
|
30073577 |
2019 |
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
The present result suggests that EGLN2 rs10680577 polymorphism is associated with cancer risk, and may act as a promising predictive biomarker for cancer risk, especially in Chinese population.
|
31414584 |
2019 |
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The present result suggests that EGLN2 rs10680577 polymorphism is associated with cancer risk, and may act as a promising predictive biomarker for cancer risk, especially in Chinese population.
|
31414584 |
2019 |
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Ins/Del polymorphism (rs10680577) in RERT-lncRNA was correlated with the risk, major clinicopathological features, and prognosis of lung cancer patients, and the patients with Ins/Del + Del/Del genotype carriers had higher expressions of RERT-lncRNA and EGLN2 than those with Ins/Ins carriers.
|
30073577 |
2019 |
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our study provided initial evidence that the insertion/deletion polymorphism rs10680577 may play a functional role in the development of CRC in the Chinese population.
|
28218358 |
2017 |
|
Stomach Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A case-control study, including 415 GC patients and 830 healthy controls, was conducted to investigate the association between GC susceptibility with a 4-bp insertion/deletion polymorphism (rs10680577) in the proximal promoter of EGLN2.
|
24517638 |
2014 |
|
Malignant neoplasm of stomach
|
|
0.010 |
GeneticVariation
|
BEFREE |
A case-control study, including 415 GC patients and 830 healthy controls, was conducted to investigate the association between GC susceptibility with a 4-bp insertion/deletion polymorphism (rs10680577) in the proximal promoter of EGLN2.
|
24517638 |
2014 |
|
Hepatocarcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Taken together, our findings provided strong evidence for the hypothesis that rs10680577 contributes to hepatocarcinogenesis, possibly by affecting RERT-lncRNA structure and subsequently EGLN2 expression, making it a promising biomarker for early diagnosis of HCC.
|
23026137 |
2012 |